<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642405</url>
  </required_header>
  <id_info>
    <org_study_id>HerlevH01</org_study_id>
    <nct_id>NCT03642405</nct_id>
  </id_info>
  <brief_title>Drug-induced Repolarization ECG Changes</brief_title>
  <official_title>Exploring the Effect of Methylphenidate and Antidepressants on Cardiac Repolarisation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have shown that the risk of developing heart arrhythmias, is increased in patients
      receiving medication for Attention-deficit hyperactivity disorder (ADHD) and depression. The
      QT-interval on a electrocardiogram (ECG) is often used to assess the patients risk of
      developing heart arrhythmias. The QT-interval defines the hearts electrical resting period
      and a long interval is linked to an increased risk of developing heart arrhythmias. In this
      project the investigators wish to examine possible side-effects in patients receiving
      medication for ADHD and depression and their dynamic QT-interval changes, by analysing the
      ECG changes that occur during &quot;Brisk Standing&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ECG changes</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>The Primary Outcome assess whether there are changes on ECG, primary the QTc-interval, in participants receiving medication for ADHD and depression.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Long QT Syndrome</condition>
  <condition>ADHD</condition>
  <condition>Depression</condition>
  <condition>Death</condition>
  <condition>Death, Sudden, Cardiac</condition>
  <condition>Romano-Ward Syndrome</condition>
  <condition>Pathologic Processes</condition>
  <condition>Heart Arrest</condition>
  <condition>Electrocardiogram: Electrical Alternans</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Death, Sudden</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <condition>Heart Defects, Congenital</condition>
  <condition>Cardiovascular Abnormalities</condition>
  <condition>Congenital Abnormalities</condition>
  <condition>Genetic Disease</condition>
  <condition>Genetic Syndrome</condition>
  <condition>Qt Interval, Variation in</condition>
  <condition>Psychiatric Disorder</condition>
  <arm_group>
    <arm_group_label>Methylphenidate-Group</arm_group_label>
    <description>The group is examined before and after intake of Methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylphenidate and know QT-prolonging SSRI</arm_group_label>
    <description>The group is examined before and after intake of Methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylphenidate and non-QT-prolonging SSRI</arm_group_label>
    <description>The group is examined before and after intake of Methylphenidate</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Electrocardiogram examination</intervention_name>
    <description>12-lead ECG monitored by Holter</description>
    <arm_group_label>Methylphenidate and know QT-prolonging SSRI</arm_group_label>
    <arm_group_label>Methylphenidate and non-QT-prolonging SSRI</arm_group_label>
    <arm_group_label>Methylphenidate-Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Echocardiography in accordance to Danish Society of Cardiology</description>
    <arm_group_label>Methylphenidate and know QT-prolonging SSRI</arm_group_label>
    <arm_group_label>Methylphenidate and non-QT-prolonging SSRI</arm_group_label>
    <arm_group_label>Methylphenidate-Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Samples</intervention_name>
    <description>Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).</description>
    <arm_group_label>Methylphenidate and know QT-prolonging SSRI</arm_group_label>
    <arm_group_label>Methylphenidate and non-QT-prolonging SSRI</arm_group_label>
    <arm_group_label>Methylphenidate-Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaire regarding patients quality of life</description>
    <arm_group_label>Methylphenidate and know QT-prolonging SSRI</arm_group_label>
    <arm_group_label>Methylphenidate and non-QT-prolonging SSRI</arm_group_label>
    <arm_group_label>Methylphenidate-Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        50 Patients treated with Methylphenidate 50 Patients treated with Methylphenidate and
        QT-prolonging SSRI 50 Patients treated with Methylphenidate and a non QT-prolonging SSRI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years old

          -  Patients treated with Methylphenidate

          -  Patients treated with Methylphenidate and QT-prolonging SSRI

          -  Patients treated with Methylphenidate and a non QT-prolonging SSRI

        Exclusion Criteria:

          -  Patients considered in an unstable phase in their psychiatric condition

          -  Patients that are not able to understand the information regarding the trial, or who
             are unable to cooperate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital at Herlev</investigator_affiliation>
    <investigator_full_name>Peter Marstrand</investigator_full_name>
    <investigator_title>MD research fellow (Ph.D)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Cardiovascular Abnormalities</mesh_term>
    <mesh_term>Romano-Ward Syndrome</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Pathologic Processes</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

